ELVN
Enliven Therapeutics Inc.
$21.75
+$0.48(+2.26%)
61
Overall
60
Value
63
Tech
--
Quality
Market Cap
$1.12B
Volume
348.76K
52W Range
$13.30 - $25.96
Target Price
$41.38
Company Overview
| Mkt Cap | $1.12B | Price | $21.75 |
| Volume | 348.76K | Change | +2.26% |
| P/E Ratio | -12.6 | Open | $21.16 |
| Revenue | -- | Prev Close | $21.27 |
| Net Income | $-89.0M | 52W Range | $13.30 - $25.96 |
| Div Yield | N/A | Target | $41.38 |
| Overall | 61 | Value | 60 |
| Quality | -- | Technical | 63 |
No chart data available
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Latest News
Enliven Therapeutics’ ELVN-001: A Promising Phase 1 Study for Chronic Myeloid Leukemia
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ELVN | $21.75 | +2.3% | 348.76K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enliven Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW